The total return over the past 12 months is -42.31% vs. +16.94% for the S&P 500. So far it's up -64.74% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (42.31%) | (62.28%) | (61.48%) | N/A | N/A | N/A |
| Total Return CAGR | (42.31%) | (62.28%) | (61.48%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Pasithea Therapeutics Corp. (KTTA)
| Year | Start price | End price | KTTA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.29 | $0.45 | (64.74%) | +14.51% | (79.25%) |
| 2025 | $3.15 | $1.29 | (59.05%) | +17.72% | (76.77%) |
| 2024 | $7.40 | $3.15 | (57.43%) | +24.89% | (82.32%) |
| 2023 | $12.84 | $7.40 | (42.37%) | +26.19% | (68.56%) |
| 2022 | $35.40 | $12.84 | (63.73%) | (18.17%) | (45.56%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
